Nov. 23 at 4:32 AM
$CDNA
Financial Results
Third Quarter Performance:
- Top-line revenue growth of 21%
- Testing services volume increased by 13%
- Adjusted EBITDA of approximately 15%
- 10% of stock repurchased year-to-date
-
$200 million in cash reserves with no debt
Revenue Cycle Management (RCM):
-
$4 million to
$6 million in Q4 attributed to prior period collections
- Appeal volume increased by over 200%
- Aiming for an average selling price (ASP) of over
$2,000 within three years
ASP and Coverage Expansion:
- October saw record cash collections, exceeding revenue recognition
- Medicare rate between
$2,700 and
$2,800
- Expanded coverage for AlloMap Heart and AlloSure by millions of lives
Operational Updates
Organ Transplant Market:
- Transplant growth continues at a 5% CAGR
- Waitlist for transplants exceeds 100,000 patients in the U.S.
IOTA Program and Kidney Protocols:
- Anticipated increase in kidney volumes by 2026
- 60 kidney programs reactivated with protocols in Q2.
